Flexion Therapeutics (FLXN) 16.08 $FLXN Flexion

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Flexion Therapeutics (FLXN) 16.08 $FLXN

Flexion Therapeutics Announces Pricing of Public Offering of Common Stock
GlobeNewswire - Wed Jun 08, 8:00AM CDT
Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced the pricing of an underwritten public offering of 5,500,000 shares of its common stock at a price to the public of $14.00 per share. The gross proceeds from this offering are expected to be approximately $77.0 million, before deducting underwriting discounts and commissions and estimated offering expenses payable by Flexion. The offering is expected to close on or about June 13, 2016, subject to customary closing conditions. Flexion has also granted the underwriters a 30-day option to purchase up to 825,000 additional shares of its common stock at the public offering price, less the underwriting discounts and commissions.
FLXN: 16.08 (-0.17), WFC: 48.02 (+0.23)

Flexion Therapeutics Announces Proposed Public Offering of Common Stock
GlobeNewswire - Tue Jun 07, 3:05PM CDT
Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced that it has commenced an underwritten public offering, subject to market and other conditions, to issue and sell approximately $60.0 million of shares of its common stock. Flexion also expects to grant the underwriters a 30-day option to purchase up to $9.0 million of additional shares of its common stock in the public offering. There can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
FLXN: 16.08 (-0.17), WFC: 48.02 (+0.23)

Flexion (FLXN) Zilretta Gets Positive FDA Guidance; Stock Up
Zacks Equity Research - Zacks Investment Research - Fri May 27, 7:12AM CDT
Shares of Flexion (FLXN) rallied after the company received positive guidance from the FDA on the New Drug Application submission for Zilretta.
FLXN: 16.08 (-0.17), ANIP: 56.37 (-0.14), PFE: 36.22 (+0.10), BMY: 75.22 (-0.06)

Flexion Therapeutics Receives Positive Guidance from FDA on New Drug Application (NDA) Submission for Zilretta(TM) for Osteoarthritis of the Knee
GlobeNewswire - Thu May 26, 6:00AM CDT
Flexion Therapeutics, Inc. (Nasdaq:FLXN) announces that yesterday it received written responses from the U.S. Food & Drug Administration (FDA) to questions the company had submitted in advance of a pre-NDA meeting regarding Flexion's lead product candidate, Zilretta (also known as FX006). The FDA clearly indicates in its responses that the safety and efficacy data from the registration program for Zilretta are "acceptable to support filing of an NDA submission." Based on this positive FDA feedback, the in-person pre-NDA meeting has become unnecessary and the FDA responses will serve as the official meeting minutes.
FLXN: 16.08 (-0.17)

Cynapsus Therapeutics Appoints Frederick Driscoll to Its Board of Directors
GlobeNewswire - Fri May 20, 5:00AM CDT
Cynapsus Therapeutics Inc. ("Cynapsus" or the "Company" (NASDAQ:CYNA) (TSX:CTH), a specialty central nervous system ("CNS" pharmaceutical company developing and preparing to commercialize a fast-acting, easy-to-use, sublingual thin film for the on-demand management of debilitating OFF episodes associated with Parkinson's disease ("PD" , today announced the appointment of Frederick W. Driscoll to its board of directors, effective May 20, 2016. Mr. Driscoll has more than 30 years of financial management experience with biotechnology and medical device companies. Mr. Driscoll will also serve on Cynapsus' audit committee.
OXGN: 0.70 (-0.03), FLXN: 16.08 (-0.17), CYNA: 16.61 (+0.27), CTH.TO: 21.24 (+0.24)

Flexion Therapeutics Reports First-Quarter 2016 Financial Results
GlobeNewswire - Thu May 12, 3:01PM CDT
-- Zilretta(TM), Flexion's non-opioid lead drug candidate (also known as FX006), completed pivotal Phase 2b and Phase 3 clinical registration trials, in patients with osteoarthritis (OA) of the knee
FLXN: 16.08 (-0.17)

Flexion Therapeutics to Report First-Quarter 2016 Financial Results on May 12, 2016
GlobeNewswire - Thu May 05, 7:30AM CDT
Flexion Therapeutics, Inc. (Nasdaq:FLXN) announced today that it will host a conference call and webcast to report its first-quarter 2016 financial results on Thursday, May 12, 2016, at 4:30 p.m. ET.
FLXN: 16.08 (-0.17)

Cytel Congratulates Flexion Therapeutics on Release of Phase 3 Data for Zilretta
BusinessWire - Thu May 05, 7:15AM CDT
Cytel Inc., a global provider of clinical research services and software, congratulates its client Flexion Therapeutics, Inc. on the release of Phase 3 data for its lead drug candidate Zilretta (also known as FX006). It was announced in February that the Phase 3 clinical trial met its primary endpoint at week 12, demonstrating highly significant (p<0.0001), durable and clinically meaningful pain relief against placebo in patients with moderate to severe osteoarthritis (OA) knee pain.
FLXN: 16.08 (-0.17)

Flexion Therapeutics Enrolls First Patient in Phase 2 Trial of Zilretta(TM) Among Type 2 Diabetes Patients With Knee Osteoarthritis
GlobeNewswire - Thu Apr 28, 3:06PM CDT
Flexion Therapeutics, Inc. (Nasdaq:FLXN) today reported it has enrolled the first patient in a clinical trial to assess the effects of its lead drug candidate, Zilretta (also known as FX006), on blood glucose levels in approximately 36 adults with osteoarthritis (OA) of the knee who also have Type 2 (adult) diabetes.
FLXN: 16.08 (-0.17)

Flexion Therapeutics to Present at 15th Annual Needham Healthcare Conference
GlobeNewswire - Thu Apr 07, 7:00AM CDT
Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced that Michael Clayman, M.D., President and Chief Executive Officer, will provide a company overview at the 15 Annual Needham Healthcare Conference on Wednesday, April 13, 2016 at 3:40 p.m. EDT in New York, NY.
FLXN: 16.08 (-0.17)

Flexion Therapeutics Announces Presentation of Results From Pivotal Phase 2b and Phase 3 Clinical Trials for Zilretta(TM) at Osteoarthritis Research Society International (OARSI) 2016 World Congress
GlobeNewswire - Mon Apr 04, 6:00AM CDT
-- Positive data from Zilretta Phase 2b and Phase 3 clinical trials demonstrate consistent efficacy across both studies with substantial and persistent pain relief
FLXN: 16.08 (-0.17)

Flexion to Present Pivotal Phase 2b and Phase 3 Results for Zilretta(TM) at Osteoarthritis Research Society International (OARSI) 2016 World Congress
GlobeNewswire - Fri Apr 01, 4:07PM CDT
Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced that it will report results from the pivotal Phase 2b and Phase 3 clinical trials of its lead drug candidate Zilretta (also known as FX006) at the Osteoarthritis Research Society International (OARSI) 2016 World Congress at the RAI Amsterdam Convention Center in Amsterdam, The Netherlands, on Saturday, April 2 at 2:00 p.m. CET/9:00 a.m. EDT.
FLXN: 16.08 (-0.17)

Flexion Reports Year-End 2015 Financial Results
GlobeNewswire - Thu Mar 10, 3:03PM CST
-- Pivotal registration trials completed in patients with osteoarthritis (OA) of the knee for Zilretta(TM), Flexion's lead drug candidate (also known as FX006)
FLXN: 16.08 (-0.17)

Flexion Therapeutics to Present at Cowen and Company's 36th Annual Health Care Conference
GlobeNewswire - Mon Mar 07, 6:00AM CST
Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced that Michael Clayman, M.D., President and Chief Executive Officer, will provide a company overview at Cowen and Company's 36 Annual Health Care Conference on Monday, March 7, 2016 at 2:00 p.m. EST at the at the Boston Marriott Copley Place.
FLXN: 16.08 (-0.17)

Flexion Therapeutics to Report Year-End 2015 Earnings Results on March 10, 2016
GlobeNewswire - Thu Mar 03, 8:00AM CST
Flexion Therapeutics, Inc. (Nasdaq:FLXN) announced today that it will host a conference call and webcast to provide an update on business operations and report its year-end 2015 financial results on Thursday, March 10, 2016, at 4:30 p.m. ET.
FLXN: 16.08 (-0.17)

Holding the Course, Oculus Innovative Sciences Delivers Revenue Growth Again
ACCESSWIRE - Tue Feb 09, 8:25AM CST
REDONDO BEACH, CA / ACCESSWIRE / February 9, 2016 / 2016 has been brutal for many sectors, but perhaps none so much as for biotechnology and pharmaceutical companies. For instance, the Nasdaq Biotechnology Index has been clubbed from 3,550 at the end of December to around 2,550, for a loss of roughly 28 percent. A wider view shows that this sector has been languishing since NBI hit an all-time high of 4,195 in July 2015. Given a $200 million market cap minimum for the index, components are diverse in size, ranging from a giant like Celgene (NASDAQ: CELG) to much smaller companies, such as NeuroDerm (NASDAQ: NDRM) and Flexion Therapeutics (NASDAQ: FLXN), demonstrating how broad the sell-off has been.
FLXN: 16.08 (-0.17), OCLS: 4.16 (-0.16), NDRM: 16.81 (-0.01), CELG: 104.52 (-0.51), CELGZ: 1.26 (-0.17)

Is Flexion Therapeutics (FLXN) Stock a Solid Choice Right Now?
Zacks Equity Research - Zacks Investment Research - Tue Dec 29, 8:02AM CST
Flexion Therapeutics is seeing solid earnings estimate revision activity and is a great company from a Zacks Industry Rank perspective
FLXN: 16.08 (-0.17)

Osteoarthritis Pain Therapeutics Pipeline Review, H2 2015 - 29 Companies & 50 Drug Profiles
M2 - Thu Dec 17, 4:34AM CST
Research and Markets (http://www.researchandmarkets.com/research/v8nbgw/osteoarthritis) has announced the addition of the "Osteoarthritis Pain - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Osteoarthritis Pain, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Osteoarthritis Pain and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - AbbVie Inc. - Addex Therapeutics Ltd - Afferent Pharmaceuticals, Inc. - Akron Molecules AG - Allergan Plc - Amgen Inc. - Ampio Pharmaceuticals, Inc. - AnaMar AB - Antibe Therapeutics, Inc. - AskAt Inc. - Astellas Pharma Inc. - AstraZeneca Plc - Boehringer Ingelheim GmbH - Bone Medical Limited - Centrexion Corporation - Convergence Pharmaceuticals Ltd. - Eli Lilly and Company - Elite Pharmaceuticals, Inc. - Flexion Therapeutics, Inc. - Grunenthal GmbH - Iroko Pharmaceuticals, LLC - Nektar Therapeutics - Nuvo Research Inc. - Pfizer Inc. - Phosphagenics Limited - Pozen, Inc. - Purdue Pharma L.P. - Regeneron Pharmaceuticals, Inc. - Rottapharm SpA Drug Profiles - (lidocaine hydrochloride tetracaine hydrochloride) - (naltrexone hydrochloride oxycodone hydrochloride) SR - A-889425 - AAT-008 - ADX-71441 - AF-219 - AKR-202 - AMAP-102 - Ampion - AQU-010 - AS-288640100 - ATB-346 - BI-1026706 - calcitonin - capsaicin - cebranopadol - celecoxib - CGS-125 - CR-4056 - CRB-0022 - CRB-0089 - duloxetine hydrochloride DR - ELS-130 - fasinumab - fulranumab - FX-005 - grapiprant - ibuprofen - MEDI-7352 - naproxen sodium - NEO-5024 - NEO-6860 - NKTR-181 - OLT-1177 - onabotulinumtoxin A For more information visit http://www.researchandmarkets.com/research/v8...oarthritis
FLXN: 16.08 (-0.17), PFE: 36.22 (+0.10), AMGN: 160.27 (-0.83), AMPE: 1.01 (-0.08), LLY: 79.43 (-0.23), NKTR: 15.09 (+0.17), AGN: 240.22 (-0.37), AZN: 30.01 (-0.10), ABBV: 64.51 (+0.35), POZN: 5.94 (-0.43), REGN: 378.55 (+0.20), PTIE: 2.26 (+0.02)

Flexion Therapeutics, Inc. Market - Global Product Pipeline Review - 2015
M2 - Tue Dec 15, 3:48AM CST
Summary
FLXN: 16.08 (-0.17)

Direction of Market Influences - Analyst Reports on Incontact, Barracuda Networks, Flexion Therapeutics and Covenant Transportation
ACCESSWIRE - Fri Dec 11, 7:25AM CST
NEW YORK, NY / ACCESSWIRE / December 11, 2015 / Moments ago, Trader's Choice released new research updates concerning several important developing situations including the following equities: Incontact Inc (NASDAQ: SAAS), Barracuda Networks Inc (NYSE: CUDA), Flexion Therapeutics Inc (NASDAQ: FLXN) and Covenant Transportation Group, Inc. (NASDAQ: CVTI). Trader's Choice has perfected the profitable art of picking stocks, cutting through the noise to deliver the top trade, every year. The full Research Packages are being made available to the public on a complimentary basis.
FLXN: 16.08 (-0.17), SAAS: 13.87 (-0.01), CUDA: 19.55 (+1.12), CVTI: 19.45 (+0.29)

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Alibaba Lawsuit Deadline Puts Disclosure Risk in Focus

Updated Category News Views 209

A calendar deadline is doing more work than any earnings headline for Alibaba shareholders this week. A securities class action notice says investors who bought or acquired Alibaba Group Holding Limited securities between May 23, 2024 and November 11, 2026 may seek appointment as lead plaintiff by January 19, 2027. That is a procedural milestone, not a verdict, and...

Continue Reading
Charter Investigation Puts ACP Exit Claims Under Lens

Updated Category News Views 258

Charter’s ACP hangover has grown from an operating headache into a governance question. Kahn Swick & Foti said on November 20, 2026, that it has begun investigating whether Charter Communications officers or directors breached fiduciary duties or otherwise broke state or federal law. That is not a finding of wrongdoing, and investors ought to keep that distinction...

Continue Reading
Domino's Probe Puts Franchise Disclosure Under Lens

Updated Category News Views 195

A franchisee's shuttered stores can turn cheerful unit-growth talk into a nasty accounting of credibility, and that is the uncomfortable territory Domino's now occupies. Kahn Swick & Foti has opened an investigation into whether Domino's officers and directors breached fiduciary duties or violated state or federal law. That is not a finding of misconduct. It is a legal...

Continue Reading
UAE Trust Model Faces Its Hardest Test During Crisis

Updated Category News Views 176

A country’s reputation is usually invisible right up until the machinery rattles. Then people, investors, trading partners and residents stop listening to polished slogans and start watching whether airports function, services hold up, information arrives, and business can keep moving. That was the useful core of Saeed Al Eter’s remarks at Ajman Media Forum 2026: soft...

Continue Reading
Persistent Dry Eye Symptoms Call for a Closer Look

Updated Category News Views 150

Eyes can turn into a stubborn little nuisance long before people realize something more complicated is going on. A bottle of artificial tears is easy to grab, cheap enough, and often perfectly sensible for a rough day of screens, wind, reading, or air conditioning. But Dr. Harlan Snyder’s point is the one worth sitting with: when dryness keeps barging back despite...

Continue Reading
CCAPP Holiday Training Targets Seasonal Recovery Strain

Updated Category News Views 126

December cheer has a nasty habit of hiding the people barely holding themselves together. CCAPP’s upcoming virtual workshop, Hope for the Holidays: Understanding Depression, Stress & Resilience During the Holiday Season, takes that uncomfortable reality seriously rather than treating it like a seasonal footnote. For behavioral health workers supporting people in...

Continue Reading
PHONO's 150 MW RE+ Win Tests Its U.S. Solar Staying Power

Updated Category News Views 118

A trade-show order book is not cash in the bank, but 150 MW is still a number worth circling in red. PHONO used RE+ 2026 in Las Vegas, held November 17 through 19, to celebrate 20 years in business, parade its solar and storage lineup, and announce new U.S. orders. In a solar market that has become touchier about provenance, compliance and delivered economics, the company...

Continue Reading
ModuleMD Takes Allergy EHR AI Beyond the Usual Hype Cycle

Updated Category News Views 215

Allergy Workflows Are Where This Has to Earn Its Keep Allergy clinics do not need another shiny dashboard clogging up a workstation. They need less typing, fewer handoffs, cleaner documentation, and fewer administrative chores slipping through the cracks while a packed day keeps moving. That is the practical lens for ModuleMD's ACAAI 2026 presentation in Phoenix: not...

Continue Reading
Mission Inn’s Lights Enter a Tender New Ownership Era

Updated Category News Views 112

A holiday spectacle can outlive the hands that hung its first bulb. Riverside is about to test that truth in public, under millions of tiny lights and the very large shadow of a family departure. The Mission Inn Festival of Lights returns in 2026 without Kelly and Duane Roberts as hotel owners for the first time in more than three decades. Duane Roberts died in 2025, the...

Continue Reading
Human Frontier Mission Puts AI Research on Display

Updated Category News Views 154

A laboratory notebook is about to become the real product in this AI experiment. Human Frontier Mission, or HFM, says it will launch globally on Nov. 24, opening a research program where domain specialists frame scientific and engineering problems while autonomous AI agents develop and test possible answers. The unusual bit is not merely handing models difficult work. It...

Continue Reading

Top 5 Most Recently Viewed Articles

Exploring the Future of Hydrogen Detection Technology and Growth

Updated Category News Views 545

Hydrogen Detection Market Size & Growth Insights The hydrogen detection market is on a remarkable trajectory, aiming to reach an impressive USD 642.39 million by 2032. This growth represents a substantial compound annual growth rate (CAGR) of 11.89% from 2024 to 2032, starting with a market valuation of USD 234.9 million in 2023. The ongoing emphasis on hydrogen as a...

Continue Reading
Insights into Novonesis’ Share Buyback Program Transactions

Updated Category News Views 336

Understanding Novonesis’ Share Buyback Program The financial landscape continuously evolves, and one significant strategy that companies often utilize is a share buyback program. Novonesis is currently engaging in such a strategy, which has piqued the interest of many investors and market analysts alike. This program allows a company to repurchase its shares from the...

Continue Reading
Discover Chippewa Boots' Newest October Selection for Workers

Updated Category News Views 250

October Boot of the Month: The Paladin and Tinsley Chippewa Boots proudly presents its October Boot of the Month: the Paladin and Tinsley, both exceptional 8-inch Waterproof Insulated Steel Toe Loggers. These boots are designed to excel in tough work environments while providing the necessary protection, comfort, and performance that professionals need. Features of the...

Continue Reading
Understanding Broadcom's Recent Options Activity and Insights

Updated Category News Views 100

Broadcom's Options Activity: What Investors Are Observing Investors with considerable capital are showing a notable interest in Broadcom (NASDAQ: AVGO), currently adopting a more cautious stance than usual. This trend is captured through significant options activity that market players should closely monitor. While the identities of these investors remain undisclosed, the...

Continue Reading
Santa Clara University Celebrates Diverse Class of 2028

Updated Category News Views 597

Welcoming a New Era at Santa Clara University Santa Clara University has kicked off a new chapter with over 1,800 enthusiastic undergraduates joining the ranks during a lively Welcome Weekend. This event was not just about filling seats; it was a whirlwind of social gatherings—from dance parties to heartfelt ceremonies—showing SCU’s determination to cultivate an...

Continue Reading